Organisation paid for research Program year 2025 Source: CMS Open Payments

Rand Eye Institute

Neither a doctor nor a teaching hospital

Research payments

$1,299,980

259 payments

Through program year 2025, Rand Eye Institute is reported as receiving $1,299,980 in research payments, across 259 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $26,408 49
2024 Research $255,990 95
2023 Research $167,490 76
2022 Research $106,720 19
2021 Research $35,832 8
2020 Research $488,669 3
2019 Research $218,871 9

Breakdown

Who paid Research payments · program years 2019–2025
  1. Novartis Pharmaceuticals Corporation $673,023 6 payments
  2. Bayer HealthCare Pharmaceuticals Inc. $418,160 171 payments
  3. Genentech, Inc. $114,028 26 payments
  4. Alcon Research LLC $71,049 20 payments
  5. Regeneron Pharmaceuticals, Inc. $19,355 2 payments
  6. Boehringer Ingelheim International GmbH $2,525 29 payments
  7. Allergan Inc. $1,402 3 payments
  8. Boehringer Ingelheim Pharmaceuticals, Inc. $239 1 payment
  9. Ocular Therapeutix, Inc. $200 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. A Multicenter Randomized Double Masked Phase 3A Study to Assess Safety and Efficacy of Brolucizumab 6 MG Q4 Weeks Compared to Aflibercept 2 MG Q4 Weeks in Patients With Neovascular Age Related MacUlar Degeneration Namd With Persistent Retinal Fluid $340,180 2 payments
  2. A 12-Month, 2-Arm, Randomized, Double-Masked, Multicenter Phase III Study Assessing the Efficacy and Safety of Brolucizumab VS. Aflibercept in Patients With Visual Impairment Due to Diabetic MacUlar Edema (Kingfisher) $320,054 2 payments
  3. BAY 865321, Aflibercept 8mg in RVO $206,183 85 payments
  4. Phase 2 of Ro7171009 in Ga $101,542 24 payments
  5. BAY865321, HD 8mg, AMD - Ph 3 $87,995 14 payments
  6. Aflibercept 8mg in RVO $73,671 46 payments
  7. Post Approval Study of the AcrySof IQ ReSTOR Toric IOL $50,660 17 payments
  8. BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of High Dose Aflibercept in Patients With Neovascular Age-Related Macular Degeneration $26,935 9 payments
  9. BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion $23,376 17 payments
  10. Post Approval Study of the AcrySof IQ ReSTOR Toric IOL (Models SND1T3-T6) $19,793 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record